Welcome to our dedicated page for Mesoblast SEC filings (Ticker: MEOBF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Mesoblast Limited SEC filings document its foreign-issuer reporting through Form 6-K submissions that incorporate Australian Securities Exchange announcements, Appendix 4C activity reports, press releases, and R&D presentation materials. The disclosures cover Ryoncil® commercialization, operating cash activity, and clinical programs built around allogeneic mesenchymal lineage stromal cell products.
The filing record also includes ASX notices for director interests, cessation of securities, unquoted equity securities, and applications for quotation of securities. These materials describe capital-structure changes, governance reporting, product and platform updates, and the company’s Form 20-F foreign private issuer framework.
Mesoblast Limited has filed a prospectus covering up to 5,000,000 ordinary shares, represented by 500,000 American Depositary Shares (ADSs), for resale by existing warrant holders. These shares are issuable upon exercise of warrants that carry an exercise price of US$16.25 per ADS.
The warrants, issued in December 2025 as part of a commitment fee tied to subscription agreements for up to US$50 million of subordinated unsecured convertible notes, have a four-year term. Two million warrants are immediately exercisable, while three million become exercisable only if Mesoblast elects to issue the convertible notes. Mesoblast will not receive proceeds from any resale of ADSs by the selling shareholders, but will receive cash upon any warrant exercises.
After this offering, Mesoblast states that 1,290,802,187 ordinary shares will be outstanding, including those underlying the ADSs offered by the shareholders. The company highlights that investing in its ADSs involves a high degree of risk and directs investors to detailed risk factors incorporated by reference.
Mesoblast Limited, an Australia-based biotechnology company, submitted a report outlining several equity-related actions first lodged with the Australian Securities Exchange on January 13, 2026. The company attached three ASX appendices to this report for investors’ reference.
One appendix covers a new issue announcement and notification of issue, conversion or payment up of unquoted equity securities (Appendix 3G). A second appendix details a new issue announcement and application for quotation of securities (Appendix 2A). A third appendix reports a new issue announcement and change of a director’s interest (Appendix 3Y). Together, these documents describe recent equity issuances and an update to director holdings, with the full details contained in the attached exhibits.
Mesoblast Limited, an Australia-incorporated company, submitted a Form 6-K as a foreign private issuer for January 2026. On January 12, 2026, the company filed a new issue announcement and a change of director’s interest notice (Appendix 3Y) with the Australian Securities Exchange, and attached this Appendix 3Y as Exhibit 99.1 to the Form 6-K. The filing indicates Mesoblast reports under Form 20-F and is signed on behalf of the company by its Company Secretary, Niva Sivakumar.
Mesoblast Limited submitted a Form 6-K as a foreign private issuer for January 2026. The company reports that on January 9, 2026 it filed a news release announcement with the Australian Securities Exchange, which is included with this submission as Exhibit 99.1 and incorporated by reference. This filing mainly serves to make that Australian disclosure available to U.S. investors.
Mesoblast Limited submitted a Form 6-K as a foreign private issuer to provide U.S. investors with information also lodged on the Australian Securities Exchange.
On January 6, 2026, the company filed in Australia a new issue announcement and notification of cessation of securities (Appendix 3H) and a new issue announcement and change of director’s interest notice (Appendix 3Y). These ASX documents are attached to the Form 6-K as Exhibits 99.1 and 99.2 and are incorporated by reference.
Mesoblast Limited submitted a Form 6-K as a foreign private issuer for January 2026. The company reports that on January 2, 2026, it filed a news release announcement with the Australian Securities Exchange, which is attached to this report as Exhibit 99.1 and incorporated by reference.
The filing is signed on behalf of Mesoblast by Company Secretary Paul Hughes and primarily serves to make the same press release available to U.S. investors through the SEC system.
Mesoblast Limited has filed a Form F-3 to register up to 5,000,000 ordinary shares, represented by 500,000 American Depositary Shares (ADSs), for resale by existing shareholders. These shares are issuable upon exercise of warrants granted in a December 2025 private placement. The ADSs trade on Nasdaq under “MESO” and each ADS equals 10 ordinary shares.
The selling shareholders, including Dr. Gregory George and Dr. William Gueck, will receive all proceeds from any ADS resales, while Mesoblast will only receive US$16.25 per ADS when warrants are exercised. The warrants cover up to 5,000,000 ordinary shares, have a four‑year term, and 3,000,000 of them become exercisable only if Mesoblast elects to issue up to US$50 million of subordinated unsecured convertible notes under related subscription agreements. Ordinary shares outstanding after the offering would be 1,290,802,187.
Mesoblast Limited submitted a foreign issuer report to the U.S. SEC for December 2025. The company notes that on December 23, 2025 it lodged with the Australian Securities Exchange a new issue announcement and a change of director’s interest notice (Appendix 3Y), which is attached as an exhibit to this report and incorporated by reference. The filing is administrative in nature and centers on disclosure of director shareholding changes and related new issue details rather than operating or financial results.